RUBILONG :

Pegylated Liposomal Doxorubicin 20mg- Emerging technology in cancer therapy (cervical and breast cancer) focuses on improving efficacy, but while at the same time reducing severe toxicity seen in the drug.

 

INSTANTINO :

Palonosetron i.e Instantino is a drug which ensures week long emesis control in patients suffering from chemo therapy induced vomiting.

 

GUTCLEAR:

Gutclear is aimed at providing superior response in the management of constipation over current therapies like lactulose and liquid paraffin combinations.Additionally, Gutclear also helps in reducing the load of ammonia (toxic substance) in hepatic encephalopathy patients by preventing absorption of ammonia from the colon.

 

BROPHYLE :

In order to control the underlying problem in asthma and COPD, our new product Brophyle  controls respiratory inflammation, stimulates production of lung surfactant, offers broncho dilation and mucociliary action thus providing more air per breath.

 

ITACT :

(Filgrastim 300mcg) In cancer patients, it is essential to stimulate granulocyte (Leukocyte) production of the body to prevent the complications of impaired immunity due to radiation and chemotherapy. Thus Itact represents a great opportunity for Zuventus Oncocare to get added in every prescription given to cancer patients.

LORETA - P is a newer fixed dose combination of Lornoxicam - 8 mg + Paracetamol - 500 mg Tablet, operating in oral NSAID market which is currently valued at Rs.1275 crs. LORETA - P potentiates the pain relief in painful inflammatory conditions with proven safety in renally compromised, hypertensive and elderly patients. Our major focused doctor specialties for LORETA - P are Orthos, CPs and GPs.

BEVON - CD is an innovative antioxidant with Omega 3 fatty acid formulations. It ensures adequate protection in chronic disorders and scavenge oxidants and provides protection in cardiac and diabetic patients. It is primarily focused amongst cardiologists and dialiectologists. It is a sugar free formulation and approved by DCGI.

C-TAX-O 400 is a line extension of our existing C-TAX-O brand which is worth Rs.11.5 crores, which provides higher dose of cefixime i.e. 400 mg. C-TAX-O 400 offers once daily dosing convenience in typhoid where the dose and duration of therapy is higher.

FALCINIL - LFX tablet is a fixed dose combination of artemether with lumefantrine in a dose of 80 mg and 480 mg respectively. It is plying in the oral antimalarial market which is worth Rs.108 crores. FALCINIL-LFX tablet provides 1 tablet bid convenience more over in the wake of chloroquine resistance to falciparum strains, the combination becomes the preferred choice.